euro-pathology-hematologic-oncology-2018-posters

2 / 6

Page 56
Notes:
conferenceseries.com
Euro Pathology 2018 | Hematologic Oncology 2018
June 20-21, 2018
Volume 8 Journal of Clinical & Experimental Pathology
ISSN : 2161-0681
15 th EUROPEAN PATHOLOGY CONGRESS
&
LEUKEMIA AND HEMATOLOGIC ONCOLOGY
June 20-21, 2018 | Paris, France
14th International Conference on
JOINT EVENT
Long-term survival case reports of two pediatric relapsed or refractory acute myeloid leukemia patients treated
with bisantrene combination therapy
Amir Sharaf
CarthaGenetics® sarl, Switzerland
Background: Bisantrene, an anthracene derivative topoisomerase II and telomerase-inhibitor, macrophage-activator without
anthracyclines’ induced-cardiotoxicity or MDR demonstrated historical CR in recurrent or refractoryAML: 23% (Marty, 1985), 50%
(Marty, 1987; Bezwoda, 1989) and 72% (Spadea, 1993). In pediatrics (Leblanc, 1994), 46% historical CR was reached in heavily
pretreated patients. We report, two AML survivors cases, decades following the study.
Case 1: Patient S (female) born January 1977, diagnosed with AML type M3 in January 1984. Initially treated with multiple lines
(cytarabine, daunorubicin, 6-mercaptopurine, methotrexate), relapsed in November 1984, treated in December 1984 with bisantrene
250mg/m2/day (7 days) followed by 6 consolidation cycles of amsacrine, cytarabine, reached historical CR in January 1985.
Patient underwent two autologous BMT in 1985. Normal Cardiac ultrasound in May 1985. Post transfusion HIV infection treated in
September 1997. Alive today, mother of 3 children.
Case 2: Patient A (female) born June 1977, diagnosed with AML type M1, t(8,21) in 1990, had multiple lines (cytarabine,
mitoxantrone, VP-16, daunorubicin). BM cryopreservation in June 1991. Relapsed in November 1991. Following additional failed
chemotherapy, received bisantrene 200mg/m2/day (5 days) + VP16 100mg/m2/day (5 days) + carboplatin 150mg/m2/day (5 days)
in December 1991, had historical CR in January 1992 with normal cardiac ultrasound. Received BM autograft after fractioned
irradiation and cyclophosphamide in February 1992. Alive today, gave birth in June 2015.
Conclusions: Long-term case reports and published bisantrene efficacy results from prior salvage studies, support renewed interest
in its clinical development as candidate with unique safety profile particularly appropriate in pediatric AML.
Biography
Amir Sharaf is a Medical Doctor with additional experience in European Market Access of innovative pharmaceuticals, including early access of drug candidates
in development for orphan indications and patients with rare diseases. His research interests include Immunology, Internal Medicine and Oncology. His research
works focus on antibodies’ diagnostic value in connective tissue diseases, as well as regulatory and economic requirements for the Market Access of Orphan and
Innovative Therapeutics including Advanced Therapeutic Medicinal Products (ATMPs) in the EU. He has also been involved in the pricing of different molecules
in Oncology and vaccination. Amir is CarthaGenetics® International Medical Manager and Business Development Director. He provides targeted methodology
approaches for CarthaGenetics® projects, as well as scientific communications to physicians and health authorities worldwide. CarthaGenetics® is a company
dedicated to the support of innovative treatments development and their access to patients in need worldwide. It was founded by Philippe Carteron de Balmont
in 2004 based on his personal commitment to find innovative early patients access to Orphan Drugs. CarthaGenetics® is now a pioneer with one of the broadest
experience in the field of Rare Diseases.
Amir Sharaf, J Clin Exp Pathol 2018, Volume 8
DOI: 10.4172/2161-0681-C1-046